Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/13/2019 08/14/2019 08/15/2019 08/16/2019 08/19/2019 Date
7342(c) 7269(c) 7230(c) 7256(c) 7281 Last
1 674 789 1 526 190 1 477 531 1 363 101 1 378 046 Volume
+0.16% -0.99% -0.54% +0.36% +0.34% Change
More quotes
Financials (USD)
Sales 2019 23 969 M
EBIT 2019 6 394 M
Net income 2019 2 292 M
Debt 2019 11 268 M
Yield 2019 3,17%
Sales 2020 26 406 M
EBIT 2020 7 249 M
Net income 2020 3 498 M
Debt 2020 11 635 M
Yield 2020 3,22%
P/E ratio 2019 49,4x
P/E ratio 2020 35,4x
EV / Sales2019 5,29x
EV / Sales2020 4,82x
Capitalization 116 B
More Financials
Company
AstraZeneca is one of the world's leading pharmaceutical groups. Net sales break down by treatment area as follows: - cardiovascular and metabolic diseases (32.3%); - respiratory diseases (20.9%); - oncology (17.9%); - other (18.5%): inflammatory and autoimmune diseases, neurological diseases,... 
Sector
Pharmaceuticals
Calendar
08/29Roadshow
More about the company
Surperformance© ratings of AstraZeneca
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTRAZENECA
02:01aASTRAZENECA : Directorate Change
AQ
08/16Correction to AstraZeneca's Lynparza Clinical Trial Article on Wednesday
DJ
08/14ASTRAZENECA : CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designa..
BU
08/14ASTRAZENECA : LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint ..
BU
08/14ASTRAZENECA : Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line ..
PU
08/14ASTRAZENECA : US FDA Names Calquence a Breakthrough Therapy
DJ
08/14ASTRAZENECA : Calquence granted US Breakthrough Therapy Designation for chronic ..
PU
08/14ASTRAZENECA : Calquence granted US Breakthrough Therapy Designat
PU
08/14ASTRAZENECA : Lynparza Phase III PAOLA-1 trial met primary endpo
PU
08/14ASTRAZENECA : Calquence granted US Breakthrough Therapy Designation
AQ
More news
Analyst Recommendations on ASTRAZENECA
More recommendations
Sector news : Pharmaceuticals - NEC
10:27aALLERGAN : Form 8.3 - Allergan Plc
DJ
03:20aNOVARTIS : to answer U.S. Senate demand for data manipulation details
RE
02:48aNOVARTIS : CEO Under Fire Over Drug Data
DJ
08/18NOVARTIS : executive sold shares before drug data manipulation made public
RE
08/18NOVARTIS : CEO Battles Fallout From Data Manipulation
DJ
More sector news : Pharmaceuticals - NEC
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,62  $
Last Close Price 88,12  $
Spread / Highest target 28,9%
Spread / Average Target 0,57%
Spread / Lowest Target -28,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Shriti Vadera Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA23.55%115 623
JOHNSON & JOHNSON1.79%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958